<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Shiga-like toxin-1 (SLT-1) is a <z:mp ids='MP_0001794'>bacterial</z:mp> toxin that kills cells by inhibiting protein synthesis </plain></SENT>
<SENT sid="1" pm="."><plain>SLT-1 is composed of one cytotoxic A-subunit and five B-subunits that bind to CD77, a cell-surface <z:chebi fb="0" ids="33563">glycolipid</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>In the human hematopoietic system, CD77 expression is restricted to a subset of activated B cells and derived <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Here we report that SLT-1 treatment of murine bone marrow ex vivo effectively cures severe combined immunodeficient mice of a human B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> xenograft while sparing <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoietic precursor cells </plain></SENT>
<SENT sid="4" pm="."><plain>Flow cytometry results using <z:chebi fb="0" ids="37926">fluorescein isothiocyanate</z:chebi>-labeled SLT-1 B-subunit show the high prevalence of expression of SLT-1 receptors (CD77) in human non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, especially follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest the use of SLT-1 for the purging of human bone marrow before autologous bone marrow transplant in the case of CD77+ B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> as just one of many possible uses </plain></SENT>
</text></document>